ACHC
Acadia Healthcare Company, Inc.
ACHC's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ACHC overall, supported by stronger fundamentals and lower modeled downside.
ACHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Weak |
ACHC's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACHC PE Valuation
ACHC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ACHC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for ACHC, with profitability improving. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ACHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | — |
| Q3 2026 | -$12.43 | -1153% |
| Q2 2026 | -$12.41 | -916% |
| Q1 2026 | -$12.20 | -698% |
| Q4 2025 | -$12.16 | -537% |
| Q3 2025 | $1.18 | -61% |
| Q2 2025 | $1.52 | +$1.59 |
| Q1 2025 | $2.04 | +$2.17 |
| Q4 2024 | $2.78 | +$3.02 |
ACHC has swung to a loss: it lost $12.43 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ACHC on earnings quality, reporting a profit while its opponent remains loss making.
ACHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $895.3M | +5.1% |
| Q2 2026 | $865.8M | -0.4% |
| Q1 2026 | $828.8M | +7.6% |
| Q4 2025 | $821.5M | +6.1% |
| Q3 2025 | $851.6M | +4.4% |
| Q2 2025 | $869.2M | +9.2% |
| Q1 2025 | $770.5M | +0.3% |
| Q4 2024 | $774.2M | +4.2% |
ACHC's revenue is growing: $895M last quarter, up 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.3% | +1.6 points |
| Q2 2026 | 2.5% | -3.2 points |
| Q1 2026 | 1.3% | -0.4 points |
| Q4 2025 | -142% | -147 points |
| Q3 2025 | 4.7% | -7.4 points |
| Q2 2025 | 5.8% | -7.6 points |
| Q1 2025 | 1.8% | -11 points |
| Q4 2024 | 4.9% | -5.9 points |
ACHC's operating margin was 6.3% last quarter, up 1.6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ACHC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ACHC on profitability, with a higher operating margin.
ACHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.1M | +$110.2M |
| Q2 2026 | $123.5M | +$157.8M |
| Q1 2026 | -$15M | +$148.1M |
| Q4 2025 | -$179.5M | -$92.7M |
| Q3 2025 | -$63M | -$35.9M |
| Q2 2025 | -$34.2M | -303% |
| Q1 2025 | -$163.2M | +$300.5M |
| Q4 2024 | -$86.8M | -$64.4M |
ACHC has burned cash in six of the last eight quarters: −$24M over the past year, against −$347M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ACHC on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +372K shares |
| 1 year | +1.3% | +1.2M shares |
| 3 years | +0.6% | +578K shares |
| 5 years | +0.9% | +857K shares |
| Available history | +4.5% | +3.9M shares |
ACHC has 92M diluted shares, up 1.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $3.2M |
| Q1 2025 | $46.9M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ACHC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ACHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 6.8x | High |
| Q2 2025 | 5.7x | High |
| Q1 2025 | 5.1x | High |
| Q4 2024 | 3.8x | Elevated |
| Q3 2024 | 3.4x | Elevated |
| Q2 2024 | 12.7x | High |
| Q1 2024 | 14.2x | High |
| Q4 2023 | 11.9x | High |
ACHC's net debt is about 6.8 years of its operating earnings (EBITDA), up from 3.4 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ACHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.3 | Overbought |
| Stochastic | 70.2 | Neutral |
ACHC's weekly RSI is 70 (overbought) and its Stochastic is 70 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ACHC PE vs Healthcare Sector
| Metric | ACHC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACHC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ACHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.5 | 20% above |
| 20 week MA | $30.9 | 23% above |
| 50 week MA | $24.8 | 52% above |
| 100 week MA | $25.9 | 46% above |
| 200 week MA | $48.6 | 22% below |
ACHC has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 22% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ACHC on trend strength, trading above more of its moving averages.
ACHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.0 | $49.3 | +49% |
| 2021 | $49.3 | $59.1 | +20% |
| 2022 | $59.1 | $83.0 | +40% |
| 2023 | $83.0 | $77.8 | -6.3% |
| 2024 | $77.8 | $38.0 | -51% |
| 2025 | $38.0 | $14.7 | -61% |
| 2026 YTD | $14.7 | $37.8 | +157% |
ACHC has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.